Animal models of obesity and diabetes mellitus

Maximilian Kleinert; Christoffer Clemmensen; Susanna M Hofmann; Mary C Moore; Simone Renner; Stephen C Woods; Peter Huypens; Johannes Beckers; Martin Hrabe de Angelis; Annette Schürmann; Mostafa Bakhti; Martin Klingenspor; Mark Heiman; Alan D Cherrington; Michael Ristow; Heiko Lickert; Eckhard Wolf; Peter J Havel; Timo D Müller; Matthias H Tschöp

doi:10.1038/nrendo.2017.161

Animal models of obesity and diabetes mellitus

Maximilian Kleinert, Christoffer Clemmensen, Susanna M Hofmann, Mary C Moore, Simone Renner, Stephen C Woods, Peter Huypens, Johannes Beckers, Martin Hrabe de Angelis, Annette Schürmann, Mostafa Bakhti, Martin Klingenspor, Mark Heiman, Alan D Cherrington, Michael Ristow, Heiko Lickert, Eckhard Wolf, Peter J Havel, Timo D Müller, Matthias H Tschöp

The August Krogh Section for Molecular Physiology

206 Citations (Scopus)

Abstract

More than one-third of the worldwide population is overweight or obese and therefore at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more potent therapeutics are urgently required. This necessitates the continued use of animal models to discover, validate and optimize novel therapeutics for their safe use in humans. In order to improve the transition from bench to bedside, researchers must not only carefully select the appropriate model but also draw the right conclusions. In this Review, we consolidate the key information on the currently available animal models of obesity and diabetes and highlight the advantages, limitations and important caveats of each of these models.

Original language	English
Journal	Nature Reviews Endocrinology
Volume	14
Pages (from-to)	140-162
Number of pages	23
ISSN	1759-5029
DOIs	https://doi.org/10.1038/nrendo.2017.161
Publication status	Published - 1 Mar 2018

Keywords

Faculty of Science
Experimental models of disease
Obesity
Type 1 diabetes
Type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrendo.2017.161

Cite this

Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., Bakhti, M., Klingenspor, M., Heiman, M., Cherrington, A. D., Ristow, M., Lickert, H., Wolf, E., Havel, P. J., Müller, T. D., & Tschöp, M. H. (2018). Animal models of obesity and diabetes mellitus. Nature Reviews Endocrinology, 14, 140-162. https://doi.org/10.1038/nrendo.2017.161

Kleinert, M , Clemmensen, C, Hofmann, SM, Moore, MC, Renner, S, Woods, SC, Huypens, P, Beckers, J, de Angelis, MH, Schürmann, A, Bakhti, M, Klingenspor, M, Heiman, M, Cherrington, AD, Ristow, M, Lickert, H, Wolf, E, Havel, PJ, Müller, TD & Tschöp, MH 2018, 'Animal models of obesity and diabetes mellitus', Nature Reviews Endocrinology, vol. 14, pp. 140-162. https://doi.org/10.1038/nrendo.2017.161

@article{02683c4907514d17bfe35e9aa180b513,

title = "Animal models of obesity and diabetes mellitus",

abstract = "More than one-third of the worldwide population is overweight or obese and therefore at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more potent therapeutics are urgently required. This necessitates the continued use of animal models to discover, validate and optimize novel therapeutics for their safe use in humans. In order to improve the transition from bench to bedside, researchers must not only carefully select the appropriate model but also draw the right conclusions. In this Review, we consolidate the key information on the currently available animal models of obesity and diabetes and highlight the advantages, limitations and important caveats of each of these models.",

keywords = "Faculty of Science, Experimental models of disease, Obesity, Type 1 diabetes, Type 2 diabetes",

author = "Maximilian Kleinert and Christoffer Clemmensen and Hofmann, {Susanna M} and Moore, {Mary C} and Simone Renner and Woods, {Stephen C} and Peter Huypens and Johannes Beckers and {de Angelis}, {Martin Hrabe} and Annette Sch{\"u}rmann and Mostafa Bakhti and Martin Klingenspor and Mark Heiman and Cherrington, {Alan D} and Michael Ristow and Heiko Lickert and Eckhard Wolf and Havel, {Peter J} and M{\"u}ller, {Timo D} and Tsch{\"o}p, {Matthias H}",

note = "CURIS 2018 NEXS 078",

year = "2018",

month = mar,

day = "1",

doi = "10.1038/nrendo.2017.161",

language = "English",

volume = "14",

pages = "140--162",

journal = "Nature Reviews Endocrinology",

issn = "1759-5029",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Animal models of obesity and diabetes mellitus

AU - Kleinert, Maximilian

AU - Clemmensen, Christoffer

AU - Hofmann, Susanna M

AU - Moore, Mary C

AU - Renner, Simone

AU - Woods, Stephen C

AU - Huypens, Peter

AU - Beckers, Johannes

AU - de Angelis, Martin Hrabe

AU - Schürmann, Annette

AU - Bakhti, Mostafa

AU - Klingenspor, Martin

AU - Heiman, Mark

AU - Cherrington, Alan D

AU - Ristow, Michael

AU - Lickert, Heiko

AU - Wolf, Eckhard

AU - Havel, Peter J

AU - Müller, Timo D

AU - Tschöp, Matthias H

N1 - CURIS 2018 NEXS 078

PY - 2018/3/1

Y1 - 2018/3/1

N2 - More than one-third of the worldwide population is overweight or obese and therefore at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more potent therapeutics are urgently required. This necessitates the continued use of animal models to discover, validate and optimize novel therapeutics for their safe use in humans. In order to improve the transition from bench to bedside, researchers must not only carefully select the appropriate model but also draw the right conclusions. In this Review, we consolidate the key information on the currently available animal models of obesity and diabetes and highlight the advantages, limitations and important caveats of each of these models.

AB - More than one-third of the worldwide population is overweight or obese and therefore at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more potent therapeutics are urgently required. This necessitates the continued use of animal models to discover, validate and optimize novel therapeutics for their safe use in humans. In order to improve the transition from bench to bedside, researchers must not only carefully select the appropriate model but also draw the right conclusions. In this Review, we consolidate the key information on the currently available animal models of obesity and diabetes and highlight the advantages, limitations and important caveats of each of these models.

KW - Faculty of Science

KW - Experimental models of disease

KW - Obesity

KW - Type 1 diabetes

KW - Type 2 diabetes

U2 - 10.1038/nrendo.2017.161

DO - 10.1038/nrendo.2017.161

M3 - Review

C2 - 29348476

SN - 1759-5029

VL - 14

SP - 140

EP - 162

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

ER -

Animal models of obesity and diabetes mellitus

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this